Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents


SCAI, new bioabsorbable stent technologies, TCT 2015, Absorb, Synergy

Synergy stent image courtesy of Boston Scientific

News | Stents Bioresorbable | October 15, 2015
October 15, 2015 — Two new advances in stent technology announced in recent days further reinforce the effectiveness of...
BIOSOLVE-II Trial results, TCT 2015, Biotronik Bioresorbable Magnesium Scaffold
News | Stents Bioresorbable | October 15, 2015
October 15, 2015 — Biotronik has announced results from the BIOSOLVE-II trial, investigating the safety and clinical...
Synergy stent
Technology | October 05, 2015
October 5, 2015 — The U.S. Food and Drug Administration (FDA) has approved Boston Scientific’s Synergy Bioabsorbable...
ABSORB STEMI TROFI II trial, ESC 2015, bioresorbable vascular scaffold, BVS, STEMI patients

Image courtesy of Abbott Vascular

Feature | Stents Bioresorbable | September 04, 2015
September 4, 2015 — A drug-eluting coronary stent made of absorbable material performed similarly to gold-standard...
Absorb, BVS, bioresorbable stent
News | Stents Bioresorbable | September 01, 2015
September 1, 2015 — A bioresorbable drug-eluting coronary stent showed similar efficacy and safety results compared to...
News | Cath Lab | August 26, 2015
August 26, 2014 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report...
bioabsorbable scaffolds, BAS, global market, 2021, 10MM, 5EU, GlobalData

Absorb BVS image courtesy of Abbott

News | Stents Bioresorbable | August 05, 2015
August 5, 2015 — The global market value for bioabsorbable scaffolds (BAS) will expand rapidly from $143.7 million in...
Boston Scientific, fully absorbable scaffold, FAST study, resorbable
Feature | Stents Bioresorbable | July 20, 2015
July 20, 2015 - Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold...
Fantom, REVA Medical, FANTOM II trial, ACC

Fantom image courtesy of REVA Medical Inc.

News | June 05, 2015
June 5, 2015 - REVA Medical Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its...
electronic stents, bioresorbable electronic stent, BES

An illustration of the bioresorbable electronic stent developed in the Korean study. It uses a magnesium stent which doubles as a wireless transmission antenna, flexible microelectronic sensors for blood flow and temperature, and a polylactic acid polymer coating with embedded drug-filled nanospheres that release the drug only when stimulated by heat or light. Image from ACS Nano.

Feature | Stents | May 28, 2015 | Dave Fornell
With the recent innovation of flexible microelectronic sensor circuits that can be made from bioresorbable materials,...
ART, PBS, pure bioresorbable scaffold, CE Mark
Feature | May 26, 2015
May 26, 2015 — Privately-held company Arterial Remodeling Technologies (ART) announced CE Mark clearance for its next-...
Boston Scientific, Synergy, EVOLVE I, EVOLVE II, EuroPCR 2015, results
News | May 22, 2015
May 22, 2015 — Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus-...
Amaranth Medical, Fortitude BRS, MEND-II, RENASCENT, EuroPCR 2015

Image courtesy of Amaranth Medical

News | May 21, 2015
May 18, 2015 — Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its...
Abbott, Absorb, dissolving stent, resorbable, CE Mark, Europe
News | May 19, 2015
May 19, 2015 — Abbott announced that it has received CE Mark for the latest advancement of its Absorb stent system,...
Boston Scientific, investors, cardiology, growth, expansion
News | May 11, 2015
May 11, 2015 — Boston Scientific Corp. presented an overview of its continued business momentum and long-term growth...